Full Press Release Details
Additional Contribution to the Liquidity Agreement with Natixis
BAGNEUX, France, December 18, 2014 - DBV Technologies (Euronext: DBV ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage
specialty biopharmaceutical company, announced today an additional contribution on December 17th, 2014 of 600,000 euros to the liquidity agreement held by Natixis in accordance with the
Charter of Ethics established by the AMAFI of March 8, 2011 and approved by the Autorit des March s Financiers.
During the half-year
report as of June 30th, 2014, the following elements were in the liquidity account:
For information, the following elements appeared on the liquidity account at the time
of the implementation of the liquidity contract:
About DBV Technologies:
DBV Technologies is developing Viaskin , an innovative new approach to the treatment of allergies
a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding
transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no
effective treatments. DBV Technologies has designed two products candidates: Viaskin Peanut and Viaskin Milk. The clinical
development program for Viaskin Peanut has received Fast Track designation from the US Food and Drug Administration.
DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of
American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT).
For more information on DBV Technologies, please visit our
website: www.dbv-technologies.com
DBV Technologies Contacts
Chief Financial Officer
Tel. : +33(0)1 55 42 78 75
DBV IR and Media Contacts